Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Clinical Trials by Condition
  • Aa
  • Adenocarcinoma, Papillary


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com





  • Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    NCT02834013
    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
    NCT01344837
    Conditions:   Endometrial Serous Adenocarcinoma;   Stage I Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer;   Stage III Uterine Corpus Cancer;   Stage IV Uterine Corpus Cancer
    Interventions:   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Immunohistochemistry Staining Method;   Other: Medical Chart Review;   Genetic: Microarray Analysis;   Other: Study of Socioeconomic and Demographic Variables;   Genetic: Western Blotting
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting
  • DCE MRI in Patients With Pancreatic Cancer
    NCT02070705
    Conditions:   Healthy Subject;   Hereditary Pancreatic Carcinoma;   Pancreatic Adenocarcinoma;   Pancreatic Intraductal Papillary Mucinous Neoplasm
    Interventions:   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Drug: Ferumoxytol
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI);   National Institute for Biomedical Imaging and Bioengineering (NIBIB)
    Recruiting
  • The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
    NCT04076514
    Condition:   Papillary Thyroid Cancer
    Intervention:   Procedure: central neck dissection
    Sponsor:   Assiut University
    Recruiting
  • Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
    NCT04129411
    Conditions:   Papillary Thyroid Cancer;   Papillary Thyroid Microcarcinoma
    Intervention:   Device: RFA
    Sponsor:   Mayo Clinic
    Not yet recruiting
  • Active Surveillance of Papillary Thyroid Microcarcinoma
    NCT02952612
    Condition:   Thyroid Cancer, Papillary
    Intervention:  
    Sponsor:   Dong Jun Lim
    Recruiting
  • The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma
    NCT02418390
    Condition:   Thyroid Cancer, Papillary
    Intervention:   Procedure: prophylactic central lymph node dissection
    Sponsor:   Seoul National University Hospital
    Recruiting
  • Studies on Tumors of the Thyroid
    NCT00001160
    Conditions:   Hurthle Cell Thyroid Cancer;   Tall Cell Variant Thyroid Cancer;   Follicular Thyroid Cancer;   Thyroid Cancer;   Papillary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
    NCT03753919
    Conditions:   Metastatic Thyroid Papillary Carcinoma;   Metastatic Thyroid Follicular Carcinoma;   Metastatic Thyroid Cancer
    Interventions:   Drug: Durvalumab;   Drug: Tremelimumab
    Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   MFAR
    Recruiting
  • Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
    NCT03506048
    Conditions:   Differentiated Thyroid Gland Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Papillary Carcinoma
    Intervention:   Drug: Lenvatinib
    Sponsors:   Emory University;   Eisai Inc.
    Recruiting
  • Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma
    NCT03889769
    Conditions:   Papillary Thyroid Cancer;   Lymph Node Metastases
    Intervention:   Diagnostic Test: OSNA test
    Sponsor:   University of Cagliari
    Recruiting
  • Effectiveness of Intraoperative Neuromonitoring of External Branch of Superior Laryngeal Nerve During Thyroid Surgery
    NCT03773120
    Condition:   Carcinoma, Papillary, Follicular
    Intervention:   Device: Using Neuromonitoring to find EBSLN
    Sponsor:   Seoul National University Hospital
    Recruiting
  • Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
    NCT03037385
    Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors;   Lung Neoplasm;   Carcinoma, Non-Small-Cell Lung;   Thyroid Diseases;   Thyroid Neoplasm;   Thyroid Cancer, Papillary;   Carcinoma, Neuroendocrine;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Disease;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Endocrine System Diseases;   Endocrine Gland Neoplasm;   Head and Neck Neoplasms;   Adenocarcinoma, Papillary;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Neuroendocrine Tumors;   Neuroectodermal Tumors;   Neoplasms, Germ Cell and Embryonal;   Neoplasms, Nerve Tissue;   Colonic Neoplasms;   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasm;   Digestive System Disease;   Gastrointestinal Disease;   Colonic Diseases;   Intestinal Disease
    Intervention:   Drug: pralsetinib (BLU-667)
    Sponsor:   Blueprint Medicines Corporation
    Recruiting
  • High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
    NCT02757859
    Conditions:   Acinar Cell Carcinoma;   Ampulla of Vater Adenocarcinoma;   Cholangiocarcinoma;   Duodenal Adenocarcinoma;   Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type;   Periampullary Adenocarcinoma
    Interventions:   Procedure: Pancreatectomy;   Other: Lavage
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting
  • Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma
    NCT04197960
    Condition:   Papillary Thyroid Carcinoma
    Interventions:   Procedure: Microwave ablation;   Procedure: Surgical resection
    Sponsor:   Chinese PLA General Hospital
    Not yet recruiting
  • A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
    NCT03469011
    Condition:   Papillary Thyroid Cancer
    Intervention:   Drug: Imatinib Oral Tablet
    Sponsors:   AHS Cancer Control Alberta;   Alberta Cancer Foundation
    Recruiting
  • Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma
    NCT03813173
    Condition:   Lymph Node Metastases
    Intervention:   Procedure: lymph node dissection
    Sponsor:   Zhejiang University
    Not yet recruiting
  • the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma
    NCT03813706
    Condition:   Lymph Node Metastases
    Intervention:   Procedure: lymph node dissection
    Sponsor:   Zhejiang University
    Not yet recruiting
  • Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer
    NCT03300284
    Condition:   Thyroid Cancer
    Intervention:   Behavioral: Questionnaires
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting
  • Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer
    NCT03271892
    Condition:   Thyroid Cancer Stage I
    Intervention:  
    Sponsors:   University Health Network, Toronto;   Ontario Ministry of Health and Long Term Care;   Canadian Cancer Society Research Institute (CCSRI)
    Recruiting
  • Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
    NCT03830242
    Conditions:   Positron-Emission Tomography;   Lymph Node Metastases;   Thyroid Cancer
    Interventions:   Diagnostic Test: 18F-FDG PET/CT dynamic scan;   Diagnostic Test: B-ultrasonography
    Sponsor:   Fifth Affiliated Hospital, Sun Yat-Sen University
    Recruiting
  • A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
    NCT01130519
    Conditions:   HLRCC;   Sporadic Papillary Renal Cell Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
    NCT02138214
    Conditions:   Stage I Papillary Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Papillary Thyroid Cancer
    Interventions:   Procedure: Thyroidectomy;   Procedure: Central lymph node dissection;   Other: Quality-of-life assessment
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting
  • Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
    NCT03470259
    Conditions:   Papillary Thyroid Cancer;   Lymph Node Metastases
    Interventions:   Drug: IV adminstration of EMI-137;   Device: Multispectral Fluorescence Reflectance Imaging;   Device: Spectroscopy
    Sponsors:   University Medical Center Groningen;   Erasmus Medical Center
    Recruiting
  • Lenvatinib and Pembrolizumab in DTC
    NCT02973997
    Conditions:   Columnar Cell Variant Thyroid Gland Papillary Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage III Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage III Thyroid Gland Follicular Carcinoma AJCC v7;   Stage III Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Hurthle Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lenvatinib;   Biological: Pembrolizumab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  • Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
    NCT03914300
    Conditions:   Differentiated Thyroid Gland Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Progressive Thyroid Carcinoma;   Refractory Thyroid Gland Carcinoma;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Hurthle Cell Carcinoma;   Thyroid Gland Papillary Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
    NCT02393690
    Conditions:   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
    Interventions:   Radiation: Iodine I-131;   Other: Placebo;   Drug: Selumetinib
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  • Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
    NCT02152995
    Conditions:   BRAF Gene Mutation;   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
    Interventions:   Procedure: Computed Tomography;   Radiation: Iodine I 124;   Radiation: Iodine I-131;   Other: Laboratory Biomarker Analysis;   Other: Pharmacodynamic Study;   Procedure: Positron Emission Tomography;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
    NCT02495103
    Conditions:   Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
    Interventions:   Drug: Vandetanib;   Drug: Metformin;   Drug: Vandetanib/Metformin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy
    NCT03454477
    Conditions:   Endoscopy;   Robotics;   Thyroidectomy;   Papillary Thyroid Carcinoma
    Interventions:   Procedure: conventional open surgery;   Procedure: endoscopic thyroidectomy;   Device: robotic thyroidectomy
    Sponsor:   Fujian Medical University
    Recruiting
  • A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
    NCT02019693
    Condition:   Kidney Cancer
    Intervention:   Drug: INC280
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy
    NCT03411187
    Conditions:   Thyroid Cancer;   Papillary Thyroid Carcinoma;   Thyroidectomy;   Endoscopy
    Interventions:   Device: used of the Pressure adjustable foot-control method;   Device: direct exhaust
    Sponsor:   Bo Wang,MD
    Recruiting
  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    NCT02761057
    Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
    NCT03866382
    Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
    NCT03899792
    Conditions:   Medullary Thyroid Cancer;   Infantile Myofibromatosis;   Infantile Fibrosarcoma;   Papillary Thyroid Cancer;   Soft Tissue Sarcoma
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting
  • Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
    NCT02568267
    Conditions:   Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
    Intervention:   Drug: Entrectinib
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
    NCT01109420
    Condition:   Non-Medullary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
    NCT04080284
    Conditions:   Endometrial Cancer;   Papillary Serous Endometrial Carcinoma;   Uterine Serous Carcinoma;   Endometrial Carcinoma;   Cancer of the Endometrium
    Intervention:   Drug: Niraparib
    Sponsors:   Northwell Health;   Tesaro, Inc.
    Not yet recruiting
  • ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
    NCT03685448
    Conditions:   Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma Type 1;   Papillary Renal Cell Carcinoma Type 2;   Chromophobe Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Xp11.2 Translocation-Related Renal Cell Carcinoma
    Intervention:   Drug: Cabozantinib
    Sponsor:   Australian and New Zealand Urogenital and Prostate Cancer Trials Group
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC